Entero Therapeutics, Inc.(ENTO)

Description: Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

---

Keywords: Biopharmaceutical Diarrhea Colitis Cystic Fibrosis Gastrointestinal Disease Metastatic Cancer Celiac Disease Exocrine Pancreatic Insufficiency Pancreatitis Gastroparesis Chronic Pancreatitis Ht4 Immune Checkpoint Inhibitor Associated Colitis Niclosamide

---

Home Page: www.enterothera.com

777 Yamato Road
Boca Raton, FL 33431
United States
Phone: 561 589 7020

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)